These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 21219261)

  • 1. Characterizing methamphetamine withdrawal in recently abstinent methamphetamine users: a pilot field study.
    Mancino MJ; Gentry BW; Feldman Z; Mendelson J; Oliveto A
    Am J Drug Alcohol Abuse; 2011 Mar; 37(2):131-6. PubMed ID: 21219261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of a controlled amphetamine withdrawal paradigm among adults who use methamphetamine: A pilot clinical trial.
    Thompson RG; Oliveto A; Thostenson JD; Wilson MP; McGaugh J; Mancino MJ
    J Psychopharmacol; 2021 Nov; 35(11):1420-1430. PubMed ID: 34697965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A placebo-controlled trial of mirtazapine for the management of methamphetamine withdrawal.
    Cruickshank CC; Montebello ME; Dyer KR; Quigley A; Blaszczyk J; Tomkins S; Shand D
    Drug Alcohol Rev; 2008 May; 27(3):326-33. PubMed ID: 18368615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pilot randomised controlled trial of modafinil during acute methamphetamine withdrawal: feasibility, tolerability and clinical outcomes.
    Lee N; Pennay A; Hester R; McKetin R; Nielsen S; Ferris J
    Drug Alcohol Rev; 2013 Jan; 32(1):88-95. PubMed ID: 22630616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The association between interleukin-8 levels and the development of withdrawal symptoms during methamphetamine abstinence.
    Feng L; He W; Lin S; Ruan Y; Yuan C; Qiu H; Ren W; He J
    Hum Psychopharmacol; 2020 Jul; 35(4):e2736. PubMed ID: 32352600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional connectivity abnormalities underlying mood disturbances in male abstinent methamphetamine abusers.
    Jiang P; Sun J; Zhou X; Lu L; Li L; Huang X; Li J; Kendrick K; Gong Q
    Hum Brain Mapp; 2021 Aug; 42(11):3366-3378. PubMed ID: 33939234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of modafinil treatment on neuropsychological and attentional bias performance during 7-day inpatient withdrawal from methamphetamine dependence.
    Hester R; Lee N; Pennay A; Nielsen S; Ferris J
    Exp Clin Psychopharmacol; 2010 Dec; 18(6):489-97. PubMed ID: 21186923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mood disturbances and regional cerebral metabolic abnormalities in recently abstinent methamphetamine abusers.
    London ED; Simon SL; Berman SM; Mandelkern MA; Lichtman AM; Bramen J; Shinn AK; Miotto K; Learn J; Dong Y; Matochik JA; Kurian V; Newton T; Woods R; Rawson R; Ling W
    Arch Gen Psychiatry; 2004 Jan; 61(1):73-84. PubMed ID: 14706946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Withdrawal symptoms in abstinent methamphetamine-dependent subjects.
    Zorick T; Nestor L; Miotto K; Sugar C; Hellemann G; Scanlon G; Rawson R; London ED
    Addiction; 2010 Oct; 105(10):1809-18. PubMed ID: 20840201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anxiety level and correlates in methamphetamine-dependent patients during acute withdrawal.
    Su H; Zhang J; Ren W; Xie Y; Tao J; Zhang X; He J
    Medicine (Baltimore); 2017 Apr; 96(15):e6434. PubMed ID: 28403074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methamphetamine withdrawal and the restoration of cognitive functions - a study over a course of 6 months abstinence.
    Proebstl L; Krause D; Kamp F; Hager L; Manz K; Schacht-Jablonowsky M; Straif M; Riebschläger M; Neumann S; Schreiber A; Soyka M; Koller G
    Psychiatry Res; 2019 Nov; 281():112599. PubMed ID: 31629302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized controlled trial of dexamphetamine maintenance for the treatment of methamphetamine dependence.
    Longo M; Wickes W; Smout M; Harrison S; Cahill S; White JM
    Addiction; 2010 Jan; 105(1):146-54. PubMed ID: 19839966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility and acceptability of approach bias modification during methamphetamine withdrawal and related methamphetamine use outcomes.
    Manning V; Garfield JBB; Mroz K; Campbell SC; Piercy H; Staiger PK; Lum JAG; Lubman DI; Verdejo-Garcia A
    J Subst Abuse Treat; 2019 Nov; 106():12-18. PubMed ID: 31540606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Impact of Exercise On Depression and Anxiety Symptoms Among Abstinent Methamphetamine-Dependent Individuals in A Residential Treatment Setting.
    Rawson RA; Chudzynski J; Gonzales R; Mooney L; Dickerson D; Ang A; Dolezal B; Cooper CB
    J Subst Abuse Treat; 2015 Oct; 57():36-40. PubMed ID: 25934458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Symptoms and sleep patterns during inpatient treatment of methamphetamine withdrawal: a comparison of mirtazapine and modafinil with treatment as usual.
    McGregor C; Srisurapanont M; Mitchell A; Wickes W; White JM
    J Subst Abuse Treat; 2008 Oct; 35(3):334-42. PubMed ID: 18329221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential benefits of quetiapine in the treatment of substance dependence disorders.
    Sattar SP; Bhatia SC; Petty F
    J Psychiatry Neurosci; 2004 Nov; 29(6):452-7. PubMed ID: 15644986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The nature, time course and severity of methamphetamine withdrawal.
    McGregor C; Srisurapanont M; Jittiwutikarn J; Laobhripatr S; Wongtan T; White JM
    Addiction; 2005 Sep; 100(9):1320-9. PubMed ID: 16128721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Withdrawal from chronic treatment with methamphetamine induces anxiety and depression-like behavior in mice.
    Ru Q; Xiong Q; Zhou M; Chen L; Tian X; Xiao H; Li C; Li Y
    Psychiatry Res; 2019 Jan; 271():476-483. PubMed ID: 30544074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methamphetamine-associated difficulties in cognitive control allocation may normalize after prolonged abstinence.
    Stock AK; Rädle M; Beste C
    Prog Neuropsychopharmacol Biol Psychiatry; 2019 Jan; 88():41-52. PubMed ID: 29953935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pexacerfont as a CRF1 antagonist for the treatment of withdrawal symptoms in men with heroin/methamphetamine dependence: a randomized, double-blind, placebo-controlled clinical trial.
    Morabbi MJ; Razaghi E; Moazen-Zadeh E; Safi-Aghdam H; Zarrindast MR; Vousoghi N; Akhondzadeh S
    Int Clin Psychopharmacol; 2018 Mar; 33(2):111-119. PubMed ID: 29064909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.